Dimensional Fund Advisors LP Boosts Holdings in Vaxcyte, Inc. $PCVX

Dimensional Fund Advisors LP raised its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 95.9% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 375,772 shares of the company’s stock after buying an additional 183,986 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Vaxcyte were worth $21,836,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of PCVX. Janus Henderson Group PLC increased its stake in shares of Vaxcyte by 2.2% during the fourth quarter. Janus Henderson Group PLC now owns 13,387,188 shares of the company’s stock worth $617,731,000 after acquiring an additional 282,985 shares during the period. T. Rowe Price Investment Management Inc. lifted its position in Vaxcyte by 35.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company’s stock valued at $521,213,000 after purchasing an additional 2,981,038 shares during the period. Wellington Management Group LLP boosted its holdings in Vaxcyte by 18.5% in the 4th quarter. Wellington Management Group LLP now owns 5,966,310 shares of the company’s stock valued at $275,286,000 after purchasing an additional 933,539 shares in the last quarter. State Street Corp increased its position in Vaxcyte by 4.1% during the 4th quarter. State Street Corp now owns 4,980,005 shares of the company’s stock worth $229,777,000 after purchasing an additional 194,116 shares during the period. Finally, Paradigm Biocapital Advisors LP increased its position in Vaxcyte by 7.5% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,068,020 shares of the company’s stock worth $187,698,000 after purchasing an additional 283,265 shares during the period. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Insider Transactions at Vaxcyte

In other news, insider Harpreet S. Dhaliwal sold 17,000 shares of Vaxcyte stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $55.00, for a total transaction of $935,000.00. Following the completion of the transaction, the insider owned 76,756 shares of the company’s stock, valued at $4,221,580. The trade was a 18.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $53.86, for a total transaction of $121,185.00. Following the completion of the sale, the chief operating officer directly owned 157,541 shares in the company, valued at approximately $8,485,158.26. The trade was a 1.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 120,646 shares of company stock worth $6,570,810 over the last ninety days. 3.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Finally, Zacks Research lowered shares of Vaxcyte from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $86.00.

Vaxcyte Price Performance

PCVX opened at $58.89 on Friday. The stock has a market cap of $8.50 billion, a P/E ratio of -7.72 and a beta of 1.23. The stock’s 50 day simple moving average is $53.72 and its 200 day simple moving average is $55.19. Vaxcyte, Inc. has a 1-year low of $29.08 and a 1-year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same period in the previous year, the company earned ($1.22) earnings per share. Research analysts expect that Vaxcyte, Inc. will post -7.91 EPS for the current fiscal year.

Key Stories Impacting Vaxcyte

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Quarterly loss beat expectations: Vaxcyte reported second-quarter 2026 EPS of negative $1.97, better than analysts’ consensus estimate of negative $2.06. However, the loss was wider than the negative $1.22 reported in the year-earlier quarter. Vaxcyte quarterly earnings release
• Positive Sentiment: Multiple clinical catalysts are ahead: Topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial are expected in the fourth quarter of 2026. Results from OPUS-2 and OPUS-3 are expected in the first half of 2027, while infant VAX-31 data are expected by the end of the first half of 2027. Vaxcyte second-quarter business update
• Positive Sentiment: Strong liquidity supports development: Vaxcyte held approximately $2.5 billion in cash, cash equivalents and investments at June 30, 2026. The balance sheet reduces near-term financing concerns as the company advances its late-stage vaccine programs and VAX-A1.
• Neutral Sentiment: Institutional ownership remains high: Several funds, including Royal Bank of Canada, UBS Asset Management and Cetera Investment Advisers, increased their positions recently. Institutional investors and hedge funds collectively own approximately 96.8% of outstanding shares.
• Negative Sentiment: Executives reported stock sales: The CFO, COO and another insider sold a combined 29,250 shares worth roughly $1.6 million. The transactions were made under pre-arranged Rule 10b5-1 plans, limiting their significance, but the sales may still weigh modestly on sentiment. Vaxcyte insider selling report
• Negative Sentiment: Losses are expected to continue: Analysts forecast a full-year 2026 loss of approximately $7.91 per share, underscoring Vaxcyte’s dependence on successful clinical execution and future commercialization.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.